Personalized Cancer Medicine: DNA Repair Alterations Are Promising Predictive Biomarkers in Cancer

DNA Repair in Cancer Therapy

Volumn , Issue , 2012, Pages 257-282

  Perry, Christina ^a   Sultana, Rebeka ^a   Madhusudan, Srinivasan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054747898     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384999-1.10012-5     Document Type: Chapter

References (256)

1. Vesell E.S. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989, 41:535-552.
2. Evans W.E., McLeod H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
3. Lee W., Lockhart A.C., Kim R.B., Rothenberg M.L. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005, 10:104-111.
4. Evans W.E. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 2003, 52(Suppl. 2: ii):10-18.
5. Efferth T., Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005, 107:155-176.
6. Yamayoshi Y., Iida E., Tanigawara Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005, 10:5-13.
7. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85.
8. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4:296-307.
9. Dudas A., Chovanec M. DNA double-strand break repair by homologous recombination. Mutat Res 2004, 566:131-167.
10. Bassing C.H., Alt F.W. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst) 2004, 3:781-796.
11. Schofield M.J., Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol 2003, 57:579-608.
12. Lees-Miller S.P., Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003, 85:1161-1173.
13. Dianov G.L., Sleeth K.M., Dianova, Allinson S.L. Repair of abasic sites in DNA. Mutat Res 2003, 531:157-163.
14. Costa R.M., Chigancas V., Galhardo Rda S., Carvalho H., Menck C.F. The eukaryotic nucleotide excision repair pathway. Biochimie 2003, 85:1083-1099.
15. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003, 21:1174-1179.
16. Farivar A.S., McCourtie A.S., MacKinnon-Patterson B.C., et al. Poly (ADP) ribose polymerase inhibition improves rat cardiac allograft survival. Ann Thorac Surg 2005, 80:950-956.
17. Bouchard V.J., Rouleau M., Poirier G.G. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003, 31:446-454.
18. Allinson S.L., Dianova Dianov GL. Poly(ADP-ribose) polymerase in base excision repair: always engaged, but not essential for DNA damage processing. Acta Biochim Pol 2003, 50:169-179.
19. Kraus W.L., Lis J.T. PARP goes transcription. Cell 2003, 113:677-683.
20. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
21. Brookes A.J. The essence of SNPs. Gene 1999, 234:177-186.
22. Wilson D.M., Bohr V.A. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 2007, 6:544-559.
23. Almeida K.H., Sobol R.W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst) 2007, 6:695-711.
24. D'Amours D., Desnoyers S., D'Silva I., Poirier G.G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999, 342(Pt 2):249-268.
25. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009, 89:23-40.
26. Durkacz B.W., Omidiji O., Gray D.A., Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596.
27. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
28. Jones C., Plummer E.R. PARP inhibitors and cancer therapy - early results and potential applications. Br J Radiol. No 2008, 1:S2-S5. 81 Spec.
29. O'Shaughnessy J., Osborne C., Pippen J., Yoffe M., Patt D., Monaghan G., et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009, 27. Abstr 3.
30. Robson C.N., Hickson I.D. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res 1991, 19:5519-5523.
31. Robson C.N., Hochhauser D., Craig R., Rack K., Buckle V.J., Hickson I.D. Structure of the human DNA repair gene HAP1 and its localisation to chromosome 14q 11.2-12. Nucleic Acids Res 1992, 20:4417-4421.
32. Evans A.R., Limp-Foster M., Kelley M.R. Going APE over ref-1. Mutat Res 2000, 461:83-108.
33. Xanthoudakis S., Miao G.G., Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci, USA 1994, 91:23-27.
34. Demple B., Herman T., Chen D.S. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. Proc Natl Acad Sci, USA 1991, 88:11450-11454.
35. Chen D.S., Herman T., Demple B. Two distinct human DNA diesterases that hydrolyze 3'-blocking deoxyribose fragments from oxidized DNA. Nucleic Acids Res 1991, 19:5907-5914.
36. Barzilay G., Hickson I.D. Structure and function of apurinic/apyrimidinic endonucleases. Bioessays 1995, 17:713-719.
37. Hickson I.D., Gorman M.A., Freemont P.S. Structure and functions of the major human AP endonuclease HAP1/Ref-1 2000, Humana Press Inc., Totowa, NJ.
38. Parsons J.L., Dianov G.L. Monitoring base excision repair proteins on damaged DNA using human cell extracts. Biochem Soc Trans 2004, 32:962-963.
39. Chou K.M., Kukhanova M., Cheng Y.C. A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA. J Biol Chem 2000, 275:31009-31015.
40. Wiederhold L., Leppard J.B., Kedar P., et al. AP endonuclease-independent DNA base excision repair in human cells. Mol Cell 2004, 15:209-220.
41. Yang H., Clendenin W.M., Wong D., et al. Enhanced activity of adenine-DNA glycosylase (Myh) by apurinic/apyrimidinic endonuclease (Ape1) in mammalian base excision repair of an A/GO mismatch. Nucleic Acids Res 2001, 29:743-752.
42. Baldwin M.R., O'Brien P.J. Human AP endonuclease 1 stimulates multiple-turnover base excision by alkyladenine DNA glycosylase. Biochemistry 2009, 48:6022-6033.
43. Hill J.W., Hazra T.K., Izumi T., Mitra S. Stimulation of human 8-oxoguanine-DNA glycosylase by AP-endonuclease: potential coordination of the initial steps in base excision repair. Nucleic Acids Res 2001, 29:430-438.
44. Marenstein D.R., Chan M.K., Altamirano A., et al. Substrate specificity of human endonuclease III (hNTH1). Effect of human APE1 on hNTH1 activity. J Biol Chem 2003, 278:9005-9012.
45. Parikh S.S., Mol C.D., Slupphaug G., Bharati S., Krokan H.E., Tainer J.A. Base excision repair initiation revealed by crystal structures and binding kinetics of human uracil-DNA glycosylase with DNA. EMBO J 1998, 17:5214-5226.
46. Waters T.R., Gallinari P., Jiricny J., Swann P.F. Human thymine DNA glycosylase binds to apurinic sites in DNA but is displaced by human apurinic endonuclease 1. J Biol Chem 1999, 274:67-74.
47. Bennett R.A., Wilson D.M., Wong D., Demple B. Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway. Proc Natl Acad Sci, USA 1997, 94:7166-7169.
48. Masuda Y., Bennett R.A., Demple B. Dynamics of the interaction of human apurinic endonuclease (Ape1) with its substrate and product. J Biol Chem 1998, 273:30352-30359.
49. Vidal A.E., Boiteux S., Hickson I.D., Radicella J.P. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J 2001, 20:6530-6539.
50. Marsin S., Vidal A.E., Sossou M., et al. Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1. J Biol Chem 2003, 278:44068-44074.
51. Dianova, Bohr V.A., Dianov G.L. Interaction of human ap endonuclease 1 with flap endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision repair. Biochemistry 2001, 40:12639-12644.
52. Tom S., Ranalli T.A., Podust V.N., Bambara R.A. Regulatory roles of p21 and apurinic/apyrimidinic endonuclease 1 in base excision repair. J Biol Chem 2001, 276:48781-48789.
53. Xanthoudakis S., Miao G., Wang F., Pan Y.C., Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 1992, 11:3323-3335.
54. Walker L.J., Robson C.N., Black E., Gillespie D., Hickson I.D. Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol Cell Biol 1993, 13:5370-5376.
55. Tell G., Damante G., Caldwell D., Kelley M.R. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxid Redox Signal 2005, 7:367-384.
56. Okazaki T., Chung U., Nishishita T., et al. A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium. J Biol Chem 1994, 269:27855-27862.
57. Fuchs S., Philippe J., Corvol P., Pinet F. Implication of Ref-1 in the repression of renin gene transcription by intracellular calcium. J Hypertens 2003, 21:327-335.
58. McHaffie G.S., Ralston S.H. Origin of a negative calcium response element in an ALU-repeat: implications for regulation of gene expression by extracellular calcium. Bone 1995, 17:11-14.
59. Bhakat K.K., Izumi T., Yang S.H., Hazra T.K., Mitra S. Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. EMBO J 2003, 22:6299-6309.
60. Vascotto C., Fantini D., Romanello M., et al. APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. Mol Cell Biol 2009.
61. Barnes T., Kim W.C., Mantha A.K., et al. Identification of apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA. Nucleic Acids Res 2009, 37:3946-3958.
62. Xanthoudakis S., Smeyne R.J., Wallace J.D., Curran T. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc Natl Acad Sci, USA 1996, 93:8919-8923.
63. Ludwig D.L., MacInnes M.A., Takiguchi Y., et al. A murine AP-endonuclease gene-targeted deficiency with post-implantation embryonic progression and ionizing radiation sensitivity. Mutat Res 1998, 409:17-29.
64. Meira L.B., Devaraj S., Kisby G.E., et al. Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. Cancer Res 2001, 61:5552-5557.
65. Ordway J.M., Eberhart D., Curran T. Cysteine 64 of Ref-1 is not essential for redox regulation of AP-1 DNA binding. Mol Cell Biol 2003, 23:4257-4266.
66. Izumi T., Brown D.B., Naidu C.V., et al. Two essential but distinct functions of the mammalian abasic endonuclease. Proc Natl Acad Sci, USA 2005, 102:5739-5743.
67. Fung H., Demple B. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol Cell 2005, 17:463-470.
68. Walker L.J., Craig R.B., Harris A.L., Hickson I.D. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res 1994, 22:4884-4889.
69. Chen D.S., Olkowski Z.L. Biological responses of human apurinic endonuclease to radiation-induced DNA damage. Ann N Y Acad Sci 1994, 726:306-308.
70. Silber J.R., Bobola M.S., Blank A., et al. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002, 8:3008-3018.
71. Ono Y., Furuta T., Ohmoto T., Akiyama K., Seki S. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutat Res 1994, 315:55-63.
72. Wang D., Luo M., Kelley M.R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004, 3:679-686.
73. McNeill D.R., Lam W., DeWeese T.L., Cheng Y.C., Wilson D.M. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 2009, 7:897-906.
74. Chen D.S., Law C., Keng P. Reduction of radiation cytotoxicity by human apurinic endonuclease in a radiation-sensitive Escherichia coli mutant. Radiat Res 1993, 135:405-410.
75. Wilson D.M., Bennett R.A., Marquis J.C., Ansari P., Demple B. Trans-complementation by human apurinic endonuclease (Ape) of hypersensitivity to DNA damage and spontaneous mutator phenotype in apn1-yeast. Nucleic Acids Res 1995, 23:5027-5033.
76. Hansen W.K., Deutsch W.A., Yacoub A., Xu Y., Williams D.A., Kelley M.R. Creation of a fully functional human chimeric DNA repair protein. Combining O6-methylguanine DNA methyltransferase (MGMT) and AP endonuclease (APE/redox effector factor 1 (Ref 1)) DNA repair proteins. J Biol Chem 1998, 273:756-762.
77. Robertson K.A., Bullock H.A., Xu Y., et al. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 2001, 61:2220-2225.
78. Xu Y., Moore D.H., Broshears J., Liu L., Wilson T.M., Kelley M.R. The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res 1997, 17:3713-3719.
79. Kakolyris S., Giatromanolaki A., Koukourakis M., et al. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). J Pathol 1999, 189:351-357.
80. Puglisi F., Aprile G., Minisini A.M., et al. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 2001, 21:4041-4049.
81. Thomson B., Tritt R., Davis M., Kelley M.R. Histology-specific expression of a DNA repair protein in pediatric rhabdomyosarcomas. J Pediatr Hematol Oncol 2001, 23:234-239.
82. Koukourakis M.I., Giatromanolaki A., Kakolyris S., et al. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int J Radiat Oncol Biol Phys 2001, 50:27-36.
83. Herring C.J., West C.M., Wilks D.P., et al. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer 1998, 78:1128-1133.
84. Wang D., Xiang D.B., Yang X.Q., et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66(3):298-304.
85. Kakolyris S., Kaklamanis L., Engels K., et al. Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence. Cancer Res 1997, 57:1794-1797.
86. Kakolyris S., Kaklamanis L., Engels K., et al. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br J Cancer 1998, 77:1169-1173.
87. Puglisi F., Barbone F., Tell G., et al. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol Rep 2002, 9:11-17.
88. Tell G., Pellizzari L., Pucillo C., et al. TSH controls Ref-1 nuclear translocation in thyroid cells. J Mol Endocrinol 2000, 24:383-390.
89. Moore D.H., Michael H., Tritt R., Parsons S.H., Kelley M.R. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin Cancer Res 2000, 6:602-609.
90. Bobola M.S., Blank A., Berger M.S., Stevens B.A., Silber J.R. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001, 7:3510-3518.
91. Kelley M.R., Cheng L., Foster R., et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001, 7:824-830.
92. Yang S., Irani K., Heffron S.E., Jurnak F., Meyskens F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther 2005, 4:1923-1935.
93. Hadi M.Z., Coleman M.A., Fidelis K., Mohrenweiser H.W., Wilson I.D. Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res 2000, 28:3871-3879.
94. Lu J., Zhang S., Chen D., et al. Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. FASEB J 2009.
95. Li D., Li Y., Jiao L., et al. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 2007, 120:1748-1754.
96. Agachan B., Kucukhuseyin O., Aksoy P., et al. Apurinic/apyrimidinic endonuclease (APE1) gene polymorphisms and lung cancer risk in relation to tobacco smoking. Anticancer Res 2009, 29:2417-2420.
97. Hu J.J., Smith T.R., Miller M.S., Mohrenweiser H.W., Golden A., Case L.D. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001, 22:917-922.
98. Su D., Ma S., Liu P., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56:281-288.
99. Gossage L., Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007, 33:565-577.
100. Suh K.W., Kim J.H., Kim Do Y., Kim Y.B., Lee C., Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?. Ann Surg Oncol 2006, 13:1379-1385.
101. Stoehlmacher J., Ghaderi V., Iobal S., et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001, 21:3075-3079.
102. Wang Z.H., Miao X.P., Tan W., Zhang X.R., Xu B.H., Lin D.X. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]. Ai Zheng 2004, 23:865-868.
103. Gurubhagavatula S., Liu G., Park S., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004, 22:2594-2601.
104. Yuan P., Liu L., Wu C., Zhong R., Yu D., Wu J., et al. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biol Ther 2010, 10:854-859.
105. Liu L., Yuan P., Wu C., et al. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 2010, December 1 [Epub ahead of print].
106. Wu X., Gu J., Wu T.T., et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006, 24:3789-3798.
107. Wei J., Liu B., Zou Z., Qian X., Zhang W., Yu L. ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy. J Clin Oncol 2007, 25(18S):2512.
108. Moreno V., Gemignani F., Landi S., et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006, 12:2101-2118.
109. Artac M., Bozcuk H., Pehlivan S., et al. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J Cancer Res Clin Oncol 2010, 136:803-809.
110. Grimminger P.P., Brabender J., Warnecke-Eberz U., et al. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res 2010, 164:e61-e66.
111. Stoehlmacher J., Park D.J., Zhang W., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91:344-354.
112. Takanami T., Nakamura J., Kubota Y., Horiuchi S. The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability. Mutat Res 2005, 582:135-145.
113. Jaremko M., Justenhoven C., Schroth W., et al. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 2007, 17:529-538.
114. Kim I.S., Kim D.C., Kim H.G., et al. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population. Cancer Genet Cytogenet 2010, 196:31-37.
115. Shim H.J., Yun J.Y., Hwang J.E., et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 2010, 101:1247-1254.
116. Bewick M.A., Conlon M.S., Lafrenie R.M. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006, 24:5645-5651.
117. Gao R., Price D.K., Dahut W.L., Reed E., Figg W.D. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther 2010, 10:13-18.
118. Liang J., Jiang T., Yao R.Y., Liu Z.M., Lv H.Y., Qi W.W. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 2010, 66:493-500.
119. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Rev 2007, 33:9-23.
120. Gillet L.C., Scharer O.D. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006, 106:253-276.
121. Reardon J.T., Sancar A. Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 2005, 79:183-235.
122. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003, 63:1311-1316.
123. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
124. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
125. Ceppi P., Volante M., Novello S., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
126. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
127. Rosell R., Cobo M., Isla D., et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol 2005, 23. Abstract No. 7002.
128. Ryu J.S., Hong Y.C., Han H.S., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
129. Zhou W., Gurubhagavatula S., Liu G., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
130. Takenaka T., Yano T., Kiyohara C., et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010, 67:101-107.
131. Suk R., Gurubhagavatula S., Park S., et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005, 11:1534-1538.
132. Li F., Sun X., Sun N., et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010, 33:489-494.
133. Wang J., Zhang Q., Zhang H., et al. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy]. Zhongguo Fei Ai Za Zhi 2010, 13:337-341.
134. Wei S.Z., Zhan P., Shi M.Q., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011, 28(1):315-321.
135. Yin M., Yan J., Voutsina A., et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 2010, 12. November [Epub ahead of print] 10.1016/j.lungcan.2010.10.011.
136. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
137. Vallbohmer D., Lenz H.J. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006, 19:425-432.
138. Yu J.J., Lee K.B., Mu C., et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000, 16:555-560.
139. Viguier J., Boige V., Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005, 11:6212-6217.
140. Park D.J., Zhang W., Stoehlmacher J., et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003, 1:162-166.
141. Metzger R., Danenberg K., Leichman C.G., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998, 4:2371-2376.
142. Kwon H.C., Roh M.S., Oh S.Y., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007, 18:504-509.
143. Yun J., Kim K.M., Kim S.T., et al. Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat 2010, 42:101-116.
144. Warnecke-Eberz U., Metzger R., Miyazono F., et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004, 10:3794-3799.
145. Joshi M.B., Shirota Y., Danenberg K.D., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005, 11:2215-2221.
146. Sobajima J., Haga N., Kumamoto K., Ishibashi K., Ishida H. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma.] Gan To Kagaku Ryoho 2010, 37:2394-2396.
147. Fareed K.R., Al-Attar A., Soomro I.N., et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010, 102:1600-1607.
148. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992, 84:1512-1517.
149. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94:703-708.
150. Doll C.M., Prystajecky M., Eliasziw M., et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 2010, 97:352-359.
151. Park J.S., Jeon E.K., Chun S.H., et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol 2011, 120(2):275-279.
152. Shao Y.Y., Kuo K.T., Hu F.C., et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol 2010, 40:286-293.
153. Chan S.H., Cheung F.M., Ng W.T., et al. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?. Int J Radiat Oncol Biol Phys 2011, 79(5):1414-1420.
154. Hoffmann A.C., Wild P., Leicht C., et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12:628-636.
155. Lunn R.M., Helzlsouer K.J., Parshad R., Umbach D.M., Harris E.L., Sanford K.K., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21:551-555.
156. Spitz M.R., Wu X., Wang Y., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001, 61:1354-1357.
157. Dybdahl M., Vogel U., Frentz G., Wallin H., Nexo B.A. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 1999, 8:77-81.
158. Qiao Y., Spitz M.R., Shen H., et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002, 23:295-299.
159. Seker H., Butkiewicz D., Bowman E.D., et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001, 61:7430-7434.
160. Rzeszowska-Wolny J., Polanska J., Pietrowska M., et al. Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 2005, 164:132-140.
161. Le Morvan V., Bellott R., Moisan F., Mathoulin-Pelissier S., Bonnet J., Robert J. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-a-vis the NCI-60 panel. Pharmacogenomics 2006, 7:843-852.
162. Zarate R.N., Arias F., Bandres E., Cubedo E., Malumbres R., Garcia-Foncillas J. Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J Gastroenterol 2006, 12:6032-6036.
163. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., Lenz H.J. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001, 61:8654-8658.
164. Yuan P., Miao X.P., Zhang X.M., et al. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer.] Zhonghua Yi Xue Za Zhi 2005, 85:972-975.
165. Camps C., Sarries C., Roig B., et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003, 4:237-241.
166. Chen H., Shao C., Shi H., Mu Y., Sai K., Chen Z. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-a-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol 2007, 82:257-262.
167. Sakano S., Wada T., Matsumoto H., et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006, 95:561-570.
168. Allan J.M., Smith A.G., Wheatley K., et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004, 104:3872-3877.
169. Vangsted A., Gimsing P., Klausen T.W., et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007, 120:1036-1045.
170. Rosell R., Taron M., Camps C., Lopez-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 2003, 39:775-786.
171. Petty W.J., Knight S.N., Mosley L., et al. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:197-202.
172. Graves R.J., Li B.F., Swann P.F. Repair of synthetic oligonucleotides containing O6-methylguanine, O6-ethylguanine and O4-methylthymine, by O6-alkylguanine-DNA alkyltransferase. IARC Sci Publ 1987, 41-43.
173. Gonzaga P.E., Brent T.P. Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide. Nucleic Acids Res 1989, 17:6581-6590.
174. Esteller M., Herman J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23:1-8.
175. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
176. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
177. Jaeckle K.A., Eyre H.J., Townsend J.J., et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16:3310-3315.
178. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
179. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
180. Sabharwal A., Middleton M.R. Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 2006, 6:355-363.
181. Wiencke J.K., Aldape K., McMillan A., et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 2005, 14:1774-1783.
182. Yang M., Coles B.F., Caporaso N.E., Choi Y., Lang N.P., Kadlubar F.F. Lack of association between Caucasian lung cancer risk and O6-methylguanine-DNA methyltransferase-codon 178 genetic polymorphism. Lung Cancer 2004, 44:281-286.
183. Abe M., Inoue R., Suzuki T. A convenient method for genotyping of human O6-methylguanine-DNA methyltransferase polymorphism. Jpn J Hum Genet 1997, 42:425-428.
184. Otsuka M., Abe M., Nakabeppu Y., Sekiguchi M., Suzuki T. Polymorphism in the human O6-methylguanine-DNA methyltransferase gene detected by PCR-SSCP analysis. Pharmacogenetics 1996, 6:361-363.
185. Imai Y., Oda H., Nakatsuru Y., Ishikawa T. A polymorphism at codon 160 of human O6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Carcinogenesis 1995, 16:2441-2445.
186. Schwarzl S.M., Smith J.C., Kaina B., Efferth T. Molecular modeling of O6-methylguanine-DNA methyltransferase mutant proteins encoded by single nucleotide polymorphisms. Int J Mol Med 2005, 16:553-557.
187. Ma S., Egyhazi S., Ueno T., et al. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003, 89:1517-1523.
188. Edara S., Kanugula S., Goodtzova K., Pegg A.E. Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine. Cancer Res 1996, 56:5571-5575.
189. Pegg A.E., Kanugula S., Edara S., Pauly G.T., Moschel R.C., Goodtzova K. Reaction of O6-benzylguanine-resistant mutants of human O6-alkylguanine-DNA alkyltransferase with O6-benzylguanine in oligodeoxyribonucleotides. J Biol Chem 1998, 273:10863-10867.
190. Xu-Welliver M., Leitao J., Kanugula S., Meehan W.J., Pegg A.E. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine. Biochem Pharmacol 1999, 58:1279-1285.
191. Margison G.P., Heighway J., Pearson S., et al. Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis 2005, 26:1473-1480.
192. Ochsenbein A.F., Schubert A.D., Vassella E., Mariani L. Quantitative analysis of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol 2010, September 21 [Epub ahead of print].
193. Busch C., Geisler J., Lillehaug J.R., Lonning P.E. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 2010, 46:2127-2133.
194. Hassel J.C., Sucker A., Edler L., et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010, 103:820-826.
195. Drummond J.T., Anthoney A., Brown R., Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271:19645-19648.
196. Friedman H.S., Johnson S.P., Dong Q., et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997, 57:2933-2936.
197. Liu L., Markowitz S., Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996, 56:5375-5379.
198. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56:3087-3090.
199. Aebi S., Fink D., Gordon R., et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997, 3:1763-1767.
200. Hamelin R., Chalastanis A., Colas C., et al. [Clinical and molecular consequences of microsatellite instability in human cancers.]. Bull du cancer 2008, 95:121-132.
201. Bendardaf R., Lamlum H., Ristamaki R., Korkeila E., Syrjanen K., Pyrhonen S. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Tumour Biol 2007, 28:212-220.
202. Jover R., Zapater P., Castells A., et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006, 55:848-855.
203. Kakar S., Aksoy S., Burgart L.J., Smyrk T.C. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 2004, 17:696-700.
204. Jansson A., Arbman G., Zhang H., Sun X.F. Combined deficiency of hMLH1, hMSH2, hMSH3 and hMSH6 is an independent prognostic factor in colorectal cancer. Int J Oncol 2003, 22:41-49.
205. Velasco A., Hewitt S.M., Albert P.S., et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 2002, 94:690-699.
206. Brueckl W.M., Heinze E., Milsmann C., et al. Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett 2004, 203:181-190.
207. Taubert H.W., Bartel F., Kappler M., et al. Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. Cancer 2003, 97:2273-2278.
208. Nakata B., Wang Y.Q., Yashiro M., et al. Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients. Oncol Rep 2003, 10:997-1000.
209. Catto J.W., Xinarianos G., Burton J.L., Meuth M., Hamdy F.C. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 2003, 105:484-490.
210. Brueckl W.M., Moesch C., Brabletz T., et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 2003, 23:1773-1777.
211. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J 2004, 10:20-26.
212. Brooks K.R., To K., Joshi M.B., et al. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 2003, 76:187-193. discussion 93.
213. Pors K., Patterson L.H. DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents. Curr Top Med Chem 2005, 5:1133-1149.
214. Maxwell J.A., Johnson S.P., McLendon R.E., et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008, 14:4859-4868.
215. Scully R., Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408:429-432.
216. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current Opin Pharmacol 2008, 8:363-369.
217. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659-1668.
218. James C.R., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007, 12:142-150.
219. Reding K.W., Bernstein J.L., Langholz B.M., et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010, 123:491-498.
220. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-2195.
221. Font A., Taron M., Gago J.L., et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011, 22:139-144.
222. Papadaki C., Tsaroucha E., Kaklamanis L., et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 2011, 104:316-323.
223. Su C., Zhou S., Zhang L., et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 2010, May 14 [Epub ahead of print.].
224. Li D., Liu H., Jiao L., et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 2006, 66:3323-3330.
225. de las Penas R., Sanchez-Ronco M., Alberola V., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17:668-675.
226. Korabiowska M., Tscherny M., Grohmann U., et al. Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. Anticancer Res 2002, 22:193-196.
227. Korabiowska M., Tscherny M., Stachura J., et al. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol 2002, 15:426-433.
228. Komuro Y., Watanabe T., Hosoi Y., et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 2002, 95:1199-1205.
229. Komuro Y., Watanabe T., Hosoi Y., et al. Prediction of tumor radiosensitivity in rectal carcinoma based on p53 and Ku70 expression. J Exp Clin Cancer Res 2003, 22:223-228.
230. Kuptsova N., Kopecky K.J., Godwin J., et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 2007, 109:3936-3944.
231. Vilmar A., Santoni-Rugiu E., Sorensen J.B. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 2010, 46:1554-1562.
232. Inada M., Sato M., Morita S., et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010, 48:729-734.
233. Gurska S., Farkasova T., Gabelova A. Radiosensitivity of cervical cancer cell lines: the impact of polymorphisms in DNA repair genes. Neoplasma 2007, 54:195-201.
234. Alsbeih G., El-Sebaie M., Al-Harbi N., Al-Buhairi M., Al-Hadyan K., Al-Rajhi N. Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int J Radiat Oncol Biol Phys 2007, 68:229-235.
235. Araujo F.D., Pierce A.J., Stark J.M., Jasin M. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002, 21:4176-4180.
236. Carles J., Monzo M., Amat M., et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006, 66:1022-1030.
237. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006, 65:646-655.
238. Stankovic T., Kidd A.M., Sutcliffe A., et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998, 62:334-345.
239. Angele S., Romestaing P., Moullan N., et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003, 63:8717-8725.
240. Damaraju S., Murray D., Dufour J., et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006, 12:2545-2554.
241. Andreassen C.N., Alsner J., Overgaard J., et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005, 75:18-21.
242. Andreassen C.N., Alsner J., Overgaard M., et al. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM-a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006, 82:577-586.
243. Bremer M., Klopper K., Yamini P., Bendix-Waltes R., Dork T., Karstens J.H. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol 2003, 69:155-160.
244. Chang-Claude J., Popanda O., Tan X.L., et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005, 11:4802-4809.
245. Moullan N., Cox D.G., Angele S., Romestaing P., Gerard J.P., Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003, 12:1168-1174.
246. Price E.A., Bourne S.L., Radbourne R., Lawton P.A., Lamerdin J., Thompson L.H., et al. Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet 1997, 23:237-247.
247. Popanda O., Tan X.L., Ambrosone C.B., et al. Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15:1048-1050.
248. Andreassen C.N., Alsner J., Overgaard M., Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003, 69:127-135.
249. Shanley S., McReynolds K., Ardern-Jones A., et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006, 12:7025-7032.
250. Shanley S., McReynolds K., Ardern-Jones A., et al. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 2006, 12:7033-7038.
251. Mangoni M., Bisanzi S., Carozzi F., et al. Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys 2010, August 11 [Epub ahead of print].
252. Zhou L., Xia J., Li H., Dai J., Hu Y. Association of XRCC1 variants with acute skin reaction after radiotherapy in breast cancer patients. Cancer Biother Radiopharm 2010, 25:681-685.
253. De Ruyck K., Van Eijkeren M., Claes K., et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005, 62:1140-1149.
254. Severin D.M., Leong T., Cassidy B., et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 2001, 50:1323-1331.
255. Zhang S., Li Q., Zhang Q., et al. Expression of ERCC1 and class III ss-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy. Int J Biol Markers 2010, 25:141-149.
256. Alsbeih G., Al-Harbi N., Al-Hadyan K., El-Sebaie M., Al-Rajhi N. Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res 2010, 173:505-511.